Hematología y Hemoterapia

Resultados: 419
Tipo Título / Nombre Autor(es) Año
A novel in vitro method to quantify the pharmacology activity of bispecific antibodies in hematological samples Primo D, Hernández P, Ghia P, Serna J de la, Ribera JM, Vives S, et al 2017
Biological characterization of ITP patients that are non-responders to traditional therapies Revilla N, Campos RM, Minano A, Velasco F, Gonzalez N, Ferrer R, et al 2017
Predictors of eartly death related to active multiple myeloma in elderly patients receiving otimized frontline treatment combinations Rodríguez Otero P, Mateos MV, Joaquín ML, Miguel Teodoro H, Enrique MO, Rosiñol L, et al 2017
Validation of precision medicine test for acute myeloid leukemia in an observational clinial trial Montesinos P, Ballesteros J, Martínez Cuadron D, Martínez López J, Errano J, Pérez de Oteyza J, et al 2017
Depth of response as surrogate marker for progression-free survival and overall survival in elderly newly diagnosed myeloma patients treated with VMP and RD: GEM2010MAS65 Mateos MV, Martínez-López J, Hernández M, Martínez R, Rosiñol L, Ocio EM, et al 2017
The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with Relapsed and Refractory Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Large, International, Multi-Center Analysis Stahl M, Deveaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al 2017
Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)— Transplant Outcomes Post HMA Therapy in a Large International Patient Cohort Stahl M, Deveaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al 2017
Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) Deveaux M, Stahl M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al 2017
Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials Barba Pere, Morgades Mireia, Montesinos Pau, Gil Cristina, Fox María Laura, Ciudad Juana, et al 2017
Bispecific Antibodies on Hematological Malignancies: A Novel Mechanism of Action That May Contribute to Therapeutic Efficacy Primo D, Hernández P, Serna J de la, Ribera JM, Vives S, Bergua J, et al 2017